Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Escitalopram
Drug ID BADD_D00809
Description Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram].[A185420] It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer.[A39738,A185819] Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class.[A185726] Escitalopram also differentiates itself from other SSRIs via allosteric action on its target - this may be the mechanism responsible for its observed superior efficacy and faster onset compared to other SSRIs.[A185825,A185726,A185822]
Indications and Usage Escitalopram is indicated for both acute and maintenance treatment of major depressive disorder (MDD) and for the acute treatment of generalized anxiety disorder (GAD).[L8513] It is additionally indicated for symptomatic relief of obsessive-compulsive disorder (OCD) in Canada.[L8516]
Marketing Status approved
ATC Code N06AB10
DrugBank ID DB01175
KEGG ID D07913
MeSH ID D000089983
PubChem ID 146570
TTD Drug ID D08RBC
NDC Product Code 80425-0320; 50090-4915; 51655-284; 53002-1431; 67296-1200; 0456-2010; 0456-2020; 69097-848; 70518-1785; 71335-1030; 0615-8366; 42708-163; 45865-699; 55700-847; 69844-079; 72189-424; 72189-451; 16729-168; 43547-281; 43547-282; 61919-652; 63187-281; 68001-456; 68071-5248; 68788-7461; 69844-077; 70934-630; 68001-454; 68071-2035; 68645-520; 68788-7510; 69844-078; 70934-957; 71205-344; 71610-425; 71610-534; 72189-449; 16571-755; 16729-170; 50090-2196; 51655-236; 53002-2438; 60760-393; 68788-7912; 70518-2317; 70771-1145; 71335-1002; 71335-1187; 71335-1307; 16571-757; 51655-766; 54838-551; 70518-2430; 70771-1147; 50090-4363; 50090-5312; 50090-6534; 51655-116; 51655-149; 69097-847; 69097-849; 70518-1876; 71205-325; 76282-250; 76282-251; 42708-155; 50090-1930; 70518-2472; 70518-3151; 70771-1146; 82982-030; 43547-280; 50090-6190; 51655-277; 55700-818; 63187-217; 67296-1597; 68001-455; 68645-519; 0456-2005; 70518-1805; 70518-2597; 71335-1571; 72189-438; 0615-8365; 72789-194; 76282-249; 16571-756; 33342-053; 60760-170; 65162-705; 71205-782; 71335-1241; 71335-2058; 0615-8348; 16729-169; 43063-661
UNII 4O4S742ANY
Synonyms Escitalopram | Escitalopram Oxalate | Lexapro
Chemical Information
Molecular Formula C20H21FN2O
CAS Registry Number 128196-01-0
SMILES CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Glossitis07.14.01.0010.000019%Not Available
Glossodynia07.14.02.0010.000019%Not Available
Glucose tolerance impaired14.06.02.001; 05.06.02.001--
Goitre14.11.01.008; 05.02.01.001--Not Available
Gout15.01.06.001; 14.09.01.001--Not Available
Haematemesis24.07.02.011; 07.12.02.002--Not Available
Haematochezia24.07.02.012; 07.12.02.0030.000095%Not Available
Haematoma24.07.01.0010.000099%
Haematuria20.02.01.006; 21.10.01.018; 24.07.01.047--
Blood urine present13.13.02.002--Not Available
Haemoglobin13.01.05.018--Not Available
Haemoglobin decreased13.01.05.003--Not Available
Haemolysis01.06.04.0020.000019%
Haemolytic anaemia01.06.03.002--Not Available
Haemorrhage in pregnancy24.07.03.015; 18.02.01.0030.000028%Not Available
Haemorrhage intracranial24.07.04.003; 17.08.01.0080.000095%
Haemorrhagic disorder24.07.01.021; 01.01.03.0040.000028%Not Available
Haemorrhagic stroke24.07.04.014; 17.08.01.0110.000057%Not Available
Haemorrhoids24.10.02.002; 07.15.03.001--
Hallucination19.10.04.0030.000254%
Hallucination, auditory19.10.04.0040.000085%Not Available
Hallucination, visual19.10.04.0070.000095%Not Available
Hallucinations, mixed19.10.04.0080.000028%Not Available
Head discomfort17.02.05.0270.000070%Not Available
Headache17.14.01.0010.002598%
Hemianopia17.17.01.012; 06.02.07.0040.000019%Not Available
Hepatic failure09.01.03.002--
Hepatic function abnormal09.01.02.0010.000095%Not Available
Hepatic necrosis09.01.07.002--
Hepatic steatosis14.08.04.005; 09.01.07.0030.000019%Not Available
The 11th Page    First    Pre   11 12 13 14 15    Next   Last    Total 36 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene